Edesa Biotech (EDSA) CEO invests $799,995.50 in private share purchase
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Edesa Biotech, Inc. Chief Executive Officer Pardeep Nijhawan acquired additional common shares in a private transaction. On June 16, 2026, he purchased 153,550 common shares at $5.21 per share, for a total of $799,995.50, and now directly holds 884,684 common shares.
He also has indirect holdings through several entities and a family trust, where he disclaims beneficial ownership beyond his pecuniary interest. These structures mean some shares are legally held by corporations and a trust associated with him rather than in his own name.
Positive
- None.
Negative
- None.
Insights
Edesa’s CEO made a sizable direct equity purchase via private placement.
CEO Pardeep Nijhawan acquired 153,550 common shares at $5.21 per share in a private placement, for an aggregate $799,995.50. This increased his directly held position to 884,684 common shares, alongside multiple indirect holdings through corporations and a family trust.
The transaction is coded as a grant/award-type acquisition but the footnote specifies a purchased private placement. This suggests capital contributed on similar terms to other buyers rather than a free award. Actual signaling value depends on how this size compares with total shares outstanding and his prior stake, which are not detailed here.
Indirect positions are held through entities wholly owned by him and as co-trustee of a family trust, with explicit disclaimers of beneficial ownership beyond his pecuniary interest. Subsequent company filings may clarify how this private placement fits into broader financing plans and ownership structure.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Nijhawan Pardeep
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Shares | 153,550 | $5.21 | $800K |
| holding | Common Shares | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
Holdings After Transaction:
Common Shares — 884,684 shares (Direct, null);
Common Shares — 402,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation)
Footnotes (1)
- On June 16, 2026, the Reporting Person purchased in a private placement, 153,550 shares of the Issuer's common shares, at a purchase price of $5.21 per share, for an aggregate purchase price of $799,995.50. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Shares acquired: 153,550 shares
Purchase price: $5.21 per share
Aggregate purchase value: $799,995.50
+5 more
8 metrics
Shares acquired
153,550 shares
Private placement on June 16, 2026
Purchase price
$5.21 per share
Private placement transaction
Aggregate purchase value
$799,995.50
Cost of 153,550 shares acquired
Direct holdings after
884,684 shares
Common shares directly owned post-transaction
Indirect holdings – Medicine Corp
402,702 shares
Held by Pardeep Nijhawan Medicine Professional Corporation
Indirect holdings – 1968160 Ontario Inc.
53,104 shares
Held by 1968160 Ontario Inc.
Indirect holdings – Digestive Health Clinic
32,013 shares
Held by The Digestive Health Clinic Inc.
Indirect holdings – Family Trust
32,609 shares
Held by The New Nijhawan Family Trust 2015
Key Terms
private placement, aggregate purchase price, wholly-owned, pecuniary interest, +2 more
6 terms
private placement financial
"purchased in a private placement, 153,550 shares of the Issuer's common shares"
A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.
aggregate purchase price financial
"at a purchase price of $5.21 per share, for an aggregate purchase price of $799,995.50"
The aggregate purchase price is the total amount a buyer pays to acquire a company, assets or securities, including the headline payment plus any assumed debt, fees, taxes and contractually required adjustments. It matters to investors because it shows the true cost of a deal and how much value must be realized after the sale — like knowing the full price of a house once you add closing costs, repairs and outstanding mortgage obligations.
wholly-owned financial
"Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person."
A wholly-owned business is one that is 100% owned by another company, meaning the parent holds all shares and controls decisions. For investors, this matters because the parent company must include the wholly-owned business’s results and liabilities in its own financial picture, so any profits, losses or risks from that unit directly affect the parent’s value—like owning an entire rental property rather than sharing it with partners.
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
beneficial ownership regulatory
"shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"for purposes of Section 16 or for any other purpose"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What did Edesa Biotech (EDSA) CEO Pardeep Nijhawan report on this Form 4?
He reported acquiring 153,550 Edesa Biotech common shares in a private placement. The shares were bought at $5.21 each, for a total of $799,995.50, increasing his directly held position to 884,684 common shares after the transaction.
What indirect holdings in Edesa Biotech (EDSA) are associated with the CEO?
Indirect holdings are reported through entities including Pardeep Nijhawan Medicine Professional Corporation, 1968160 Ontario Inc., The Digestive Health Clinic Inc., and The New Nijhawan Family Trust 2015. He disclaims beneficial ownership beyond his pecuniary interest in these indirect positions.
How large was the CEO’s cash commitment in this Edesa Biotech (EDSA) transaction?
The CEO’s cash commitment was $799,995.50 for 153,550 common shares. This amount comes from multiplying the $5.21 per-share purchase price by the number of shares acquired in the private placement described in the Form 4 footnote.